Liver fibrosis represents a critical pathological hallmark in the progression of chronic liver diseases and serves as a key transition point from metabolic liver injury to irreversible cirrhosis. In the context of metabolic dysfunction–associated steatohepatitis (MASH, formerly referred to as NASH), fibrotic remodeling of the liver is a major determinant of long-term clinical outcomes and therapeutic success.
Despite extensive investment in antifibrotic drug development, clinical translation remains challenging. One of the primary obstacles lies in the limited predictive value of conventional preclinical models, which often fail to faithfully reproduce the metabolic, inflammatory, and fibrotic features observed in human disease.
Leveraging its established non-human primate (NHP) translational research capabilities, Prisys Biotech has developed a controlled cynomolgus monkey MASH model that is intrinsically linked to liver fibrosis, providing a robust and clinically relevant platform for antifibrotic drug evaluation.
From MASH to Liver Fibrosis: A Closely Linked and Traceable Pathological Continuum
Clinical and experimental evidence indicates that MASH is not merely an inflammatory condition, but a complex pathological state characterized by metabolic dysfunction, hepatocellular injury, and a substantially increased risk of fibrosis progression. In early disease stages, hepatic steatosis and inflammation frequently coexist and interact under sustained metabolic stress, collectively driving structural remodeling and fibrogenic responses in the liver.
The cynomolgus monkey MASH model developed at Prisys Biotech is designed in alignment with this clinical understanding. Rather than focusing on a single pathological endpoint, the model captures the dynamic evolution of liver pathology, enabling longitudinal assessment of fibrogenesis in the context of metabolic liver disease.
By establishing a MASH background with progressive fibrotic features, this model is particularly well suited for the evaluation of therapeutic strategies targeting early-to-intermediate stages of liver fibrosis.
Why a Diet-Induced Model Over Spontaneous Fibrosis in Aged Primates?
In non-human primate research, spontaneous liver fibrosis identified in aged animals may appear to reflect natural disease progression. However, such models present substantial limitations for translational drug development, including:
- High inter-animal variability and limited baseline consistency
- Unpredictable disease onset and progression rates
- Extended study timelines and reduced reproducibility
Constraints on study design and statistical power
In contrast, diet-induced MASH-associated fibrosis models offer a higher degree of experimental control, which is essential for rigorous pharmacological evaluation. The Prisys Biotech platform emphasizes:
- Defined induction conditions enabling controlled disease progression
- Dynamic stratification of animals based on multi-parameter assessments
- Improved baseline homogeneity for efficacy studies
- Greater flexibility in study duration and endpoint definition
This approach allows investigators to focus not only on the presence of fibrosis, but also on the quantitative assessment of fibrotic development and therapeutic intervention under controlled conditions.
Multidimensional Assessment Supporting Fibrosis-Focused Research
To ensure robust model validation and drug efficacy evaluation, Prisys Biotech has established an integrated assessment framework combining clinically relevant methodologies:
Biochemical and metabolic monitoring
Longitudinal evaluation of liver function parameters and systemic metabolic markers provides essential context for disease progression.
Quantitative imaging-based evaluation
Clinically translatable imaging modalities are applied to assess hepatic fat accumulation and tissue mechanical properties in a non-invasive, repeatable manner.
Histopathological confirmation
Liver tissue collected at predefined study milestones undergoes comprehensive histological analysis using internationally recognized scoring systems to confirm MASH activity and fibrosis stage.
The convergence of these datasets enables objective, quantitative, and reproducible evaluation of fibrosis-related outcomes.
A Translational Platform for Antifibrotic Drug Development
The cynomolgus monkey MASH-associated fibrosis model at Prisys Biotech has been successfully applied across multiple internal and collaborative research programs. The platform is particularly suitable for:
- Early efficacy screening of antifibrotic candidates
- Mechanistic studies within a metabolically relevant disease context
- Biomarker exploration linking imaging, serum markers, and histology
- Integrated assessment of efficacy and safety in mid- to long-term dosing studies
By anchoring fibrosis evaluation within a metabolically driven disease framework, the platform enhances decision-making confidence prior to clinical transition.
In liver fibrosis drug development, the critical challenge is not merely the ability to induce fibrotic changes, but the ability to generate reproducible, controllable, and clinically predictive data that inform translational decisions.
Prisys Biotech's non-human primate MASH-associated liver fibrosis research platform is designed to meet this challenge by combining physiological relevance, controlled disease induction, and multidimensional quantitative assessment-supporting more informed progression from preclinical studies to clinical development.
We welcome scientific discussions to explore how this platform may be adapted to support your specific research objectives.
